

DAFTAR PUSTAKA

- Abbate, M., Zoja, C., & Remuzzi, G. (2006). How Does Proteinuria Cause Progressive Renal Damage? *J Am Soc Nephrol*, 17: 2974 –2984. doi: 10.1681/ASN.2006040377.
- Abdur, R., Stephen, M., & Setter, M. H. (2011). Drug-Induced Glucose Alterations Part 2: Drug-Induced Hyperglycemia. *Diabetes Spectr*, 24(4): 234–238. <https://doi.org/10.2337/diaspect.24.4.234>.
- Abe, M., & Zadeh, K. K. (2015). Haemodialysis-Induced Hypoglycaemia and Glycaemic Disarrays. *Nat Rev Nephrol*, 11(5): 302–313. doi:10.1038/nrneph.2015.38.
- Abe, M., Kaizu, K., & Matsumoto, K. (2007). Plasma Insulin Is Removed by Hemodialysis: Evaluation of the Relation Between Plasma Insulin and Glucose by Using a Dialysate with or without Glucose. *Ther Apher Dial*, 11(4): 280-7. doi: 10.1111/j.1744-9987.2007.00491.
- ADA. (2020). Pharmacologic Approaches to Glycemic Treatment. *American Diabetes Association*, 43(suppl1):S98.
- Alhadramy, M. S. (2016). Diabetes and Oral Therapies: a Review of Oral Therapies for Diabetes Mellitus. *Journal of Taibah University Medical Sciences*, 11(4): 317–329. doi: 10.1016/j.jtumed.2016.02.001.
- Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). Diabetic Kidney Disease: Challenges, Progress, and Possibilities. *Clin J Am Soc Nephrol*, 12: 2032–2045. doi: <https://doi.org/10.2215/CJN.11491116>.
- Alsahli, M., & Gerich, J. E. (2015). Hypoglycemia in Patients with Diabetes and Renal Disease. *J. Clin. Med.*, 4: 948-964. doi:10.3390/jcm4050948.
- Alviar, C. L., Devarapally, S., Nadkarni, G., Romero, J., Benjo, A. M., & Javed, F. (2013). Efficacy and Safety of Dual Calcium Channel Blocker Therapy for the Treatment of Hypertension: A Meta-analysis. *American Journal of Hypertension*, 26(2): 287-297. <https://doi.org/10.1093/ajh/hps009>.
- Ayoub, P.; Héту, P. O.; Cormier, M.; Benoit, A.; Palumbo, A.; Dubé, M. C.; Gosselin, S.; Ghannoum, M. (2017). Toxicokinetics of Metformin During Hemodialysis. *Kidney Int Rep*, 2(4): 759-762. doi: 10.1016/j.ekir.2017.02.017.
- Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. (2018). *Laporan Nasional RISKESDAS Tahun 2018*. Jakarta: Kementerian Kesehatan RI.
- Barone, R. J., Beresan, M., Pattin, M., Gimenez, N. S., & Berga, G. (2017). Management of Type 2 Diabetes in Patients with Chronic Kidney Disease. *Arch Clin Nephrol*, 3(1): 053-056. DOI: 10.17352/acn.000026.

- Bell, K., Twiggs, J., & Olin, B. R. (2015). Hypertension : The Silent Killer : Updated JNC-8 Guideline Recommendations. *Alabama Pharm Association*, 1–8.
- Berlin, O., Oswari, L. D., & Susilawati. (2019). Comparison of Blood Pressure and Blood Glucose Levels in Chronic Kidney Failure Patients Before and After Hemodialysis Treatment in RSMH Palembang. *Majalah Kedokteran Sriwijaya*, 51(2): 86-96.
- Betônico, C. C., Titan, S. M., Correa-Giannella, M., Nery, M., & Queiroz, M. (2016). Management of Diabetes Mellitus in Individuals with Chronic Kidney Disease: Therapeutic Perspectives and Glycemic Control. *Clinics (Sao Paulo)*, 71(1):47-53. doi: 10.6061/clinics/2016(01)08.
- Brunton, L. L., Chabner, B. A., & Knollmann, B. C. (2011). *Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 12th Ed.* New York: The McGraw-Hill Companies, Inc.
- Carrero, J. J., Hecking, M., Chesnaye, N. C., & Jager, K. J. (2018). Sex and Gender Disparities in the Epidemiology and Outcomes of Chronic Kidney Disease. *Nature Reviews Nephrology*, 1-14. doi:10.1038/nrneph.2017.181 .
- Centers for Disease Control and Prevention. (2021). *Chronic Kidney Disease in the United States: Disease Control and Prevention*. Atlanta: GA: US Department of Health and Human Services.
- Chang, T. I., Tatoian, E. T., Montez-Rath, M. E., & Chertow, G. M. (2021). Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis: A Cluster Randomized Trial. *KIDNEY360*, 2: 1752–1760. doi: <https://doi.org/10.34067/KID.0001922021>.
- Depkes RI. (2008). *Pedoman Pelayanan Hemodialisis di Sarana Pelayanan Kesehatan*. Jakarta: Direktorat Jenderal Bina Pelayanan Medik.
- Dhrik, M., & Prasetya, A. A. (2019). Kajian Pemilihan Obat Antihipertensi pada Penderita Hipertensi dengan Gagal Ginjal Kronis yang Menjalani Hemodialisis. *Act Holis Pharm*, 2(1): 18-26.
- DiPiro, J. T., Yee, G. C., Posey, L. M., & Haines, S. T. (2020). *Pharmacotherapy: A Pathophysiologic Approach, 11th Edition*. New York: McGraw-Hill Education.
- Ellison, D. H. (2019). Clinical Pharmacology in Diuretic Use. *CJASN*, 14: 1248–1257. doi: <https://doi.org/10.2215/CJN.09630818>.
- Foy, M. C., Vaishnav, J., & Sperati, C. (2019). Drug-Induced Hypertension. *Endocrinol Metab Clin N Am*, 48(4): 859-873. <https://doi.org/10.1016/j.ecl.2019.08.013>.
- Frishman, W. H., Cheng-Lai, A., & Nawarskas, J. (2005). Current Cardiovascular Drugs. *Current Science Group*, p. 152. ISBN 978-1-57340-221-7.

- Gajjala, P. R., Sanati, M., & Jankowski, J. (2015). Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities. *Front. Immunol*, 6:340. doi: 10.3389/fimmu.2015.00340.
- Georgianos, P. I., & Agarwal, R. (2016). Pharmacotherapy of Hypertension in Chronic Dialysis Patients. *Clin J Am Soc Nephrol*, 11: 1-14. doi: 10.2215/CJN.00870116.
- Gormer, B. (2014). *Farmakologi Antihipertensi. Terjemahan oleh D. Lyrwati*. Jakarta: EGC.
- Goudarzian, A. H., Nia, H. S., Okamoto, Y., Rhee, C. M., Mcfarlane, P., & Nejad, F. G. (2015). Adverse effects of hemodialysis on kidney patients: how good the evidence is. *Int J Med Invest*, 4(4), 357-361.
- Hall, J. E., Granger, J. P., Jones, D. W., & Hall, M. E. (2017). Pathophysiology of Hypertension. *Hurst's The Heart*, 14e. <https://accessmedicine.mhmedical.com/content.aspx?bookid=2046&s>.
- Hengyu, T., Junbo, Y., Zhuochao, X., & Jialin, L. (2018). Gliquidone Alleviates Diabetic Nephropathy by Inhibiting Notch/Snail Signaling Pathway. *Cellular Physiology and Biochemistry*, 51(5): 2085–2097. <https://doi.org/10.1159/000495827>.
- Holstein, A., & Egberts, E. H. (2003). Risk of Hypoglycaemia with Oral Antidiabetic Agents in Patients with Type 2 Diabetes. *Exp Clin Endocrinol Diabetes*, 111: 405-414.
- Ignacak, E., Cieniawski, D., Bętkowska-Prokop, A., Osuch, C., Kuźniewski, M., & Sułowicz, W. (2017). Beneficial Effect of Kidney Transplantation from a Deceased Donor on Severe Chronic Refractory. *BMC nephrology*, 18(1): 248. DOI : [hps://doi.org/10.1186/s12882-017-0662-y](https://doi.org/10.1186/s12882-017-0662-y).
- Inker, L. A.; Astor, B. C.; Fox, C. H.; Isakova, T.; Lash, J. P.; Peralta, C. A.; Tamura, M. K.; Feldman, H. I. (2014). KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. *American Journal of Kidney Diseases*, 63(5): 713–735. doi:10.1053/j.ajkd.2014.01.416.
- Inrig, J. K. (2010). Antihypertensive Agents in Hemodialysis Patients: A Current Perspective. *Semin Dial*, 23(3): 290-297. doi:10.1111/j.1525-139X.2009.00697.x.
- Jager, K. J., Kovesdy, C., Langham, R., Rosenberg, M., Jha, V., & Zoccali, C. (2019). A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. *Kidney Int.*, 96:1048–1050.
- Kadir, A. (2016). Hubungan Patofisiologi Hipertensi dan Hipertensi Renal. *Jurnal Ilmiah Kedokteran*, 5(1): 15-25.

- KDIGO. (2013). Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International Supplements*, 3(1): 5-150.
- KDIGO. (2021). Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *International Society of Nephrology*, 99(3): 1-87.
- KDIGO. (2022). Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *International Society of Nephrology*, 102(5): 1-127.
- Khalil, H., & Zeltser, R. (2022). *Antihypertensive Medications*. Treasure Island (FL): StatPearls Publishing LLC.
- Ku, E., Lee, B. J., Wei, J., & Weir, M. R. (2019). Hypertension in CKD: Core Curriculum 2019. *Am J Kidney Dis*, 74(1): 120-131. doi: 10.1053/j.ajkd.2018.12.044.
- Lemeshow, S., Hosmer, D. W., Klar, J., & Lwanga, S. K. (1997). *Besar Sampel dalam Penelitian Kesehatan*. Yogyakarta: Universitas Gadjah Mada Press.
- Leonard, C., Han, X., Brensinger, C. M., Warren, B. B., Serena, C., James, H. F., & Sean, H. (2018). Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study. *Pharmacoepidemiol Drug Saf*, 27(1): 9-18. doi:10.1002/pds.4337.
- Lin, Y., & Ma, L. (2018). Blood pressure lowering effect of calcium channel blockers on perioperative hypertension: A systematic review and meta-analysis. *Medicine (Baltimore)*, 97(48):e13152. doi: 10.1097/MD.00000000000013152.
- Liu, S. Y., Tian, H. M., Liao, D. Q., Chen, Y. F., Gou, Z. P., Xie, X. Y., & Li, X. J. (2015). The effect of gliquidone on KATP channels in pancreatic beta-cells, cardiomyocytes, and vascular smooth muscle cells. *Diabetes Res Clin Pract*, 109: 334-339.
- Mariana, S., & Astutik, S. (2018). Hubungan Dampak Terapi Hemodialisis terhadap Kualitas Hidup Pasien dengan Gagal Ginjal. *IJNSP*, 1(2): 41-52. DOI: <https://doi.org/10.24853/ijnsp.v1i2.41-52>.
- Moini, J. (2019). Pathophysiology of Diabetes. *Epidemiology of Diabetes*, 25-43. doi:10.1016/b978-0-12-816864-6.00003-1.
- Morales, J., & Schneider, D. (2014). Hypoglycemia. *The American Journal of Medicine*, 127(10): S17-S24.
- Muchtar, N. R., Tjitrosantoso, H., & Bodhi, W. (2015). Studi Penggunaan Obat Antihipertensi pada Pasien Gagal Ginjal Kronik yang Menjalani Perawatan di RSUP Prof. dr. R. D. Kandou Manado Periode Juli 2013-Juni 2014. *PHARMACON*, 4(3): 22-28.

- Nachawati, D., & Patel, J. B. (2022). *Alpha Blockers*. Bethesda: Treasure Island, StatPearls Publishing. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK556066/>.
- Nakamura, Y.; Hasegawa, H.; Tsuji, M.; Udaka, Y.; Mihara, M.; Shimizu, T.; Inoue, M.; Goto, Y.; Gotoh, H.; Inagaki, M.; Oguchi, K. (2015). Diabetes Therapies in Hemodialysis Patients: Dipeptidase-4 Inhibitors. *World J Diabetes*, 6(6): 840-9. doi: 10.4239/wjd.v6.i6.840.
- Nissenson, A. R., & Fine, R. N. (2008). *Handbook of Dialysis Therapy 4th Ed*. Oxford: Saunders Elsevier Inc.
- Ou, S. H., Chen, H. Y., Fang, N. W., Yin, C. H., Chen, C. L., & Chen, J. S. (2021). Effect of anti-diabetic drugs in dialysis patients with diabetes: a nationwide retrospective cohort study. *Cardiovasc Diabetol*, 20: 179. <https://doi.org/10.1186/s12933-021-01364-w>.
- PERHI. (2019). *Konsensus Penatalaksanaan Hipertensi 2019*. Jakarta: Perhimpunan Dokter Hipertensi Indonesia.
- PERKENI. (2021). *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia*. Jakarta: Perhimpunan Endokrinologi Indonesia.
- PERNEFRI. (2003). *Konsensus Dialisis*. Jakarta: Perhimpunan Nefrologi Indonesia.
- PERNEFRI. (2018). *11th Report of Indonesian Renal Registry*. Jakarta: Perkumpulan Nefrologi Indonesia.
- PIONAS. (2022). *Biguanida*. Retrieved from <https://pionas.pom.go.id/ioni/bab-6-sistem-endokrin/61-diabetes/612-antidiabetik-oral/6122-biguanida>, Diakses pada 20 November 2022 pukul 17:40.
- Pranandari, R., & Supadmi, W. (2015). Faktor risiko gagal ginjal kronik di unit hemodialisis rsud wates kulon progo. *Majalah Farmaseutik*, 11(2): 315-320.
- Qayyum, M. A. (2016). Management of diabetes in patients on hemodialysis. *Urol Nephrol Open Access J*, 3(5):153–154.
- Rehani, P. R., Iftikhar, H., Nakajima, M., Tanaka, T., Jabbar, Z., & Rehani, R. N. (2019). Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA). *J Diabetes Res*, 4267357. doi: 10.1155/2019/4267357.
- Rivandi, J., & Yonata, A. (2015). Hubungan Diabetes Melitus dengan Kejadian Gagal Ginjal Kronik. *Majority*, 4(9): 27-34.
- Sanjaya, A. A., Santhi, D. G., & Lestari, A. (2019). Gambaran Anemia pada Pasien Gagal Ginjal Kronik di RSUP Sanglah pada Tahun 2016. *JMU*, 8(6): 1-6.

- Setyorini, F. D. (2019). Studi Penggunaan Antihipertensi pada Pasien Gagal Ginjal Kronik yang Menjalani Rawat Jalan di RSUD dr. Iskak Tulungagung Periode Januari-Maret 2018. *SKRIPSI*, 47-52.
- Sinha, A. D., & Agarwal, R. (2019). Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. *Clinical Journal of the American Society of Nephrology*, 14(5): 757-764.
- Sun, C. Y., Lee, C. C., & Wu, M. S. (2009). Hypoglycemia in diabetic patients undergoing chronic hemodialysis. *Therapeutic Apheresis and Dialysis*, 13(2): 95–102. <https://doi.org/10.1111/j.1744-9987.2009.00662.x>.
- Suparti, S., & Solikhah, U. (2016). Perbedaan Kualitas Hidup Pasien Gagal Ginjal Kronik Ditinjau dari Tingkat Pendidikan, Frekuensi dan Lama Hemodialisis di RSUD Goeteng Taroenadibrata Purbalingga. *MEDISAINS*, 14(2): 50-58.
- Tai, S. L., Chih, C. H., Ming, H. L., Vin, C. W., & Yung, M. C. (2022). Trends in the incidence and prevalence of end-stage kidney disease requiring dialysis in Taiwan: 2010–2018. *Journal of the Formosan Medical Association*, 121(1): S5-S11. <https://doi.org/10.1016/j.jfma.2021.12.013>.
- Terra, S. G. (2003). Angiotensin Receptor Blockers. *Circulation*, 107:e215-e216. DOI: 10.1161/01.CIR.0000072344.12827.13.
- Unger, T., Borghi, C., Charchar, F., Khan, N. A., & Poulter, N. R. (2020). ISH Global Hypertension Practice Guidelines. *Hypertension*, 75:1334-1357. DOI: 10.1161/HYPERTENSIONAHA.120.15026.
- Vaidya, S. R., & Aeddula, N. R. (2022). *Chronic Renal Failure*. StatPearls Publishing: Available from: <https://www.ncbi.nlm.nih.gov/books/NBK535404/>.
- Webster, A. C., Nagler, E. V., Morton, R. L., & Masson, P. (2017). Chronic Kidney Disease. *The Lancet*, 389(10075): 1238–1252.
- Wua, T. C., Langi, F. L., & Kaunang, W. P. (2019). Kualitas Hidup Pasien Hemodialisis di Unit Hemodialisa Rumah Sakit Umum Pusat Prof. Dr. R.D. Kandou Manado. *Jurnal KESMAS*, 8(7): 127-136.
- Xu, X., Zhu, R., Ying, J., Zhao, M., Wu, X., Cao, G., & Wang, K. (2020). Nephrotoxicity of Herbal Medicine and Its Prevention. *Front Pharmacol*, 11:569551. <https://doi.org/10.3389/fphar.2020.569551>.
- Zanchi, A., Lehmann, R., & Philippe, J. (2012). Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology. *Swiss Med Wkly*, 142:w13629. doi: 10.4414/smw.2012.13629.
- Zhang, Q., Lv, X. Y., & Yang, Y. M. (2015). Megaloblastic anemia with hypotension and transient delirium as the primary symptoms: report of a case. *International journal of clinical and experimental medicine*, 8(10): 18879–18883.